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OBJECTIVES We sought to evaluate the effect of therapy with intravenous immune globulin on recovery of
left ventricular function in women presenting with peripartum cardiomyopathy.
BACKGROUND Peripartum cardiomyopathy is a rare complication of pregnancy that results in significant
morbidity and mortality in women of childbearing age. Intravenous immune globulin has
been reported to improve left ventricular systolic function in patients with acute dilated
cardiomyopathy and myocarditis, but its effectiveness in peripartum cardiomyopathy is
unknown.
METHODS In this retrospective study, we compared the clinical outcomes of six women with peripartum
cardiomyopathy treated with intravenous immune globulin (2 g/kg) with those of 11 recent
historical control subjects. All women in the study were referred between 1991 and 1998 with
class II to IV heart failure and a left ventricular ejection fraction of ,0.40. Left ventricular
ejection was reassessed during early follow-up (6.1 6 2.9 months).
RESULTS The two groups did not differ in terms of baseline left ventricular ejection fraction, left
ventricular end-diastolic diameter, months to presentation, age or multiparity. The improve-
ment in left ventricular ejection fraction in patients treated with immune globulin was
significantly greater than in the conventionally treated group (increase of 26 6 8 ejection
fraction units vs. 13 613, p 5 0.042).
CONCLUSIONS In this small retrospective study of women with peripartum cardiomyopathy, patients treated
with immune globulin had a greater improvement in ejection fraction during early follow-up
than patients treated conventionally. Given the poor prognosis of women with peripartum
cardiomyopathy who do not improve, this therapy merits further study. (J Am Coll Cardiol
1999;34:177–80) © 1999 by the American College of Cardiology
Peripartum cardiomyopathy is an uncommon complication
of pregnancy occurring in 1:1,300 to 1:4,000 live births (1).
This myocardial disorder classically presents in the last
trimester or in the first few months postpartum (2) and is
clinically indistinguishable from other forms of idiopathic
dilated cardiomyopathy (3,4). Though its etiology remains
unknown, most theories have focused on the hemodynamic
(5,6) and immunologic stresses (7) of pregnancy. An im-
mune pathogenesis is supported by the frequent finding of
lymphocytic myocarditis on endomyocardial biopsy (8–11),
and the fact that multiparity, or previous exposure to fetal or
placental antigen, is a significant risk factor (2). In contrast
to patients with idiopathic dilated cardiomyopathy, signif-
icant improvement in myocardial function is seen in 30% to
50% of patients in the first six months after presentation
(12). However, for those patients who do not recover
normal or near normal function, the prognosis is similar to
other forms of dilated cardiomyopathy, with the overall rate
of death or transplantation ranging from 29% to 43%
(13,14).
Current therapeutic options consist of conventional sup-
portive therapy for congestive heart failure (15,16). A single
nonrandomized study (10) suggested immunosuppression
may benefit women with biopsy-proven myocarditis. How-
ever, given the risks of immunosuppressive therapy, and the
absence of a proven benefit in the myocarditis treatment
trial (17), this therapy has not been widely utilized. In
addition, the prevalence of myocarditis on biopsy series with
peripartum cardiomyopathy ranges from 9% to 78% (10,11),
and the role of immune modulatory therapy in the large
percentage of women with negative biopsies remains un-
known.
Intravenous immune globulin, a concentrated preparation
of pooled polyclonal human antibodies (immunoglobulin
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G), has significant immune modulatory properties (18) and
has been reported to improve left ventricular function in
children with acute dilated cardiomyopathy and myocarditis
(19). We have previously noted similar findings in adult
patients (20); however, the effects of immune globulin
therapy in peripartum cardiomyopathy have not previously
been reported.
Since 1996, the management of women with severe left
ventricular dysfunction from peripartum cardiomyopathy at
the University of Pittsburgh Medical Center has included
administration of high dose immune globulin in addition to
conventional therapy. Given the importance of early recov-
ery of myocardial function in determining prognosis with
this disorder, the purpose of this retrospective study is to
evaluate the effect of immune globulin therapy on left
ventricular systolic function within the first year after
presentation.
METHODS
Study subjects. Seventeen consecutive women with peri-
partum cardiomyopathy referred to the University of Pitts-
burgh Medical Center for evaluation between December
1991 and February 1998 were retrospectively identified. All
patients presented with New York Heart Association class
II to IV heart failure within the first six months postpartum
with a left ventricular ejection fraction of ,0.40, and were
referred to the University of Pittsburgh Medical Center
within the first year after delivery. All patients had an
extensive cardiac evaluation to rule out other forms of
cardiac disease.
Treatment group. The treatment group consisted of six
women who presented between August of 1996 and Feb-
ruary of 1998, and were treated with immune globulin in
addition to conventional therapy. Immune globulin therapy
consisted of 2 g/kg of immune globulin given as 1 g/kg q.d.
intravenously on two consecutive days. Conventional ther-
apy included angiotensin-converting enzyme inhibitors,
digoxin and loop diuretics in all six patients. Only one
patient was treated with a beta-adrenergic blocking agent.
Two of six required inotropic therapy at the time of
treatment, and one required intra-aortic balloon pump
support.
Control group. The control group consisted of 11 women,
10 presenting before August of 1996, and one woman
presenting after the initiation of investigations with immune
globulin for whom therapy was recommended but was
declined. Conventional therapy consisted of angiotensin-
converting enzyme inhibitors in nine, digoxin in nine and
beta-blockers in three. Two patients required inotropic
support, and one required an intra-aortic balloon pump at
the time of referral.
Assessment of left ventricular ejection fraction (LVEF).
Baseline LVEF was measured by transthoracic echocardi-
ography using modified Simpson’s rule at the time of
referral to the University of Pittsburgh Medical Center in 14
patients, and radionucleotide angiography in three. One
control patient died within the first week after presentation
and was excluded from the follow-up analysis. In the
remaining patients, LVEF was reassessed during the early
follow-up at a mean of 6.1 6 2.9 months (range 3 to 12).
The time to follow-up assessment was similar for both
groups (treatment 5.5 6 2.4, control 6.4 6 3.2 months).
Left ventricular ejection fraction was reassessed using the
same methodology as the baseline assessment for all but one
patient.
Statistical analysis. Changes in LVEF over time were
assessed using two-way repeated measures analysis of vari-
ance, with time being the within-subjects variable. Assess-
ment of the effect of therapy over time was made by
evaluating the interaction term in the model. Values are
presented as mean 6 standard deviation.
RESULTS
The clinical characteristics of the treatment group and
control subjects are listed in Table 1. The treatment and
control groups did not differ in age, degree of parity, months
postpartum, left ventricular diastolic diameter or LVEF.
Myocardial biopsies were performed in 11 of 17 total
patients and revealed evidence of lymphocytic myocarditis
in only one.
The change in LVEF from baseline to follow-up for both
groups is depicted in Figure 1. The clinical outcomes of the
control group are consistent with previous reports of the
natural history of peripartum cardiomyopathy. Left ventric-
ular ejection fraction improved at least 10 ejection fraction
(EF) units in four of 11; however, only two achieved an
LVEF .0.50, and four patients were either dead, or were
left with severe left ventricular dysfunction. The mean
improvement of ejection fraction for the 10 surviving
control subjects was 13 6 13 EF units.
The mean improvement of EF with immune globulin
was 26 6 8 EF units, significantly greater than in control
subjects (p 5 0.042 for the interaction of therapy and time;
for the individual main effects, p , 0.001 for time and p 5
0.69 for initial group assignment). All patients treated with
immune globulin had an improvement in EF of at least 10
EF units and three had normalized their LVEF at the time
of follow-up assessment. Only one patient was left with
severe left ventricular dysfunction. This patient was referred
late, seven months after her last pregnancy, required two
inotropes at the time of therapy and subsequently required
biventricular device support within one week of treatment
Abbreviations and Acronyms
EF 5 ejection fraction
LVEF 5 left ventricular ejection fraction
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with immune globulin. Of note, this patient’s ventricular
function recovered sufficiently to allow discontinuation of
biventricular device support. Right ventricular assist was
discontinued within one week, and by 30 days there was
echocardiographic evidence of left ventricular recovery. Left
ventricular support was successfully removed two months
later and this patient was discharged from the hospital on
medical therapy and LVEF reassessed two months after
device removal.
DISCUSSION
In the present study, the use of high dose immune globulin
was associated with a marked improvement in LVEF during
early follow-up, twice that seen in a recent historical control
group. All but one patient in the treatment group achieved
an ejection fraction .35% at six months, and these results
closely parallel previously reported outcomes of treatment
with immune globulin in children and adults with primary
dilated cardiomyopathy and myocarditis. Given immune
globulin’s effects as an immune-modulating agent, the
apparent efficacy in the disorder supports the hypothesis
that peripartum cardiomyopathy is driven by an autoim-
mune pathogenesis.
The majority of patients in this study had endomyocardial
biopsies that were negative for cellular inflammation. This
may imply that humoral factors, autoantibodies, cytokines
or other anti-inflammatory mediators are more important in
the pathogenesis of peripartum cardiomyopathy than cellu-
lar autoimmunity. However, sampling error and delays in
presentation limit the sensitivity of endomyocardial biopsy,
making interpretation of negative biopsies problematic.
Conceivably cellular mechanisms may play a more signifi-
cant role than was demonstrated by the current study.
Immunologic changes of pregnancy. Adaptive immuno-
logic changes occur during pregnancy which allow maternal
tolerance of paternal antigens in the developing fetus (21).
Table 1. Clinical Characteristics at the Time of Referral
Patient
Age
(yr) Parity Months Biopsy LVDD LVEF
Conventional therapy
1 35 1 1 5.7 0.37
2 31 1 4 Negative 5.4 0.21
3 28 1 2 6.7 0.35
4 34 3 7 6.3 0.34
5 17 1 1 Negative 6.9 0.07
6 39 5 1 6.6 0.23
7 32 1 1 5.2 0.18
8 19 1 3 Negative 5.0 0.10
9 27 2 1 5.1 0.37
10 20 1 3 Negative 7.4 0.25
11 28 3 2 Negative 7.2 0.13
Mean 6 SD* 28.2 6 7.0 1.8 6 1.3 2.4 6 1.9 6.1 6 0.9 0.24 6 0.11
Conventional therapy plus
immune globulin
12 22 2 7 Negative 7.1 0.13
13 22 4 6 Myocarditis 4.5 0.30
14 28 2 1 Negative 5.4 0.25
15 19 2 4 Negative 5.9 0.14
16 31 3 2 Negative 6.2 0.20
17 36 4 2 Negative 5.7 0.17
Mean 6 SD* 26.3 6 6.5 2.8 6 1.0 3.6 6 2.4 5.8 6 0.9 0.20 6 0.07
*No significant differences between conventional therapy and immune globulin treated groups.
LVDD 5 left ventricular end-diastolic diameter (cm); LVEF 5 left ventricular ejection fraction at the time of referral;
Months 5 time from delivery until referral; Parity 5 number of pregnancies.
Figure 1. Change in left ventricular ejection fraction (LVEF)
during early follow-up. *Improvement significantly greater than
with conventional therapy alone, p 5 0.042.
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This includes the induction of suppressor cells that act to
effectively suppress maternal rejection (22). These adaptive
changes during pregnancy are associated with the clinical
observation that autoimmune disorders such as rheumatoid
arthritis and multiple sclerosis (23), which affect women
during their reproductive years, tend to have lower relapse
rates during pregnancy itself with a marked increase in the
first few months postpartum. In a subset of women with
recurrent spontaneous abortions, a defect in the suppression
of maternal immunity has been postulated and immune
globulin has been utilized to try to limit maternal rejection
of the fetus (24).
Multiparity is a significant risk factor for elevations of
antibodies directed against foreign human leukocyte anti-
gens (25), demonstrating the importance of maternal–fetal
interactions in this form of humoral immunity which
complicates cardiac transplantation. High dose immune
globulin has been show to reduce the titer of autoantibodies
in patients awaiting transplantation (26). Plasmaphoresis
has also been utilized effectively for this purpose (27), and
may be an alternative to immune globulin therapy in
peripartum cardiomyopathy. Recently a small controlled
study of immunoadsorption in idiopathic dilated cardiomy-
opathy (28) demonstrated significant improvements in left
ventricular function, suggesting that therapies directed
against humoral autoimmunity may have a significant role
in the treatment of this and related disorders.
Although the improvement seen in this retrospective
analysis appears promising, the absence of a randomized
control group limits our ability to draw firm conclusions
about the efficacy of immune globulin without a larger
multicenter controlled trial. The IMAC trial, a randomized
prospective placebo-controlled trial of immune globulin in a
related population of adult patients with myocarditis and
recent onset idiopathic dilated cardiomyopathy, has com-
pleted the enrollment phase with outcome data available by
late 1999. The results of this trial of immune globulin in a
similar disorder may yield important insights in the poten-
tial use of this therapy in women with peripartum cardio-
myopathy.
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